PURPOSE: To evaluate if an individual's level of meaning/peace (M/P) predicts various quality of life (QOL) and mental well-being measures. To identify targets that might enhance the overall spiritual well-being and QOL of ovarian cancer patients. METHODS: Multi-site analysis of women with newly diagnosed stages II-IV ovarian, primary peritoneal, or fallopian tube cancer. Patients completed the following surveys: Functional Assessment of Chronic Illness Therapy-Ovarian (FACT-O), Functional Assessment of Chronic Illness Therapy-Spiritual (FACIT-Sp), Edmonton Symptom Assessment System (ESAS), Hospital Anxiety and Depression Scale (HADS), Templer's Death Anxiety Scale (DAS), Herth Hope Index (HHI), and Brief Multidimensional Measure of Religiousness/Spirituality (BMMRS). Linear regression models were created to examine the effect of M/P (FACIT-Sp) upon QOL, symptoms, and other measures of mental well-being. These models adjusted for the effect of site, race, age, stage, anaphylaxis to chemotherapy, and partner status as potential confounders. RESULTS: This study enrolled 104 patients from three separate sites. After adjusting for potential confounders, it was found that higher M/P predicted better QOL (FACT-O) (p < 0.0001). Higher M/P also predicted decreased death anxiety, depression, and anxiety (p ≤ 0.005). Finally, higher M/P predicted increased hope and coping scores (p ≤ 0.0005). CONCLUSIONS: Level of M/P is associated with several important mental and physical health states. This information may allow providers to identify patients at increased risk for mental/physical distress and may facilitate early referral to targeted psychotherapy interventions focused on improving patient QOL and decreasing anxiety and depression.
PURPOSE: To evaluate if an individual's level of meaning/peace (M/P) predicts various quality of life (QOL) and mental well-being measures. To identify targets that might enhance the overall spiritual well-being and QOL of ovarian cancerpatients. METHODS: Multi-site analysis of women with newly diagnosed stages II-IV ovarian, primary peritoneal, or fallopian tube cancer. Patients completed the following surveys: Functional Assessment of Chronic Illness Therapy-Ovarian (FACT-O), Functional Assessment of Chronic Illness Therapy-Spiritual (FACIT-Sp), Edmonton Symptom Assessment System (ESAS), Hospital Anxiety and Depression Scale (HADS), Templer's Death Anxiety Scale (DAS), Herth Hope Index (HHI), and Brief Multidimensional Measure of Religiousness/Spirituality (BMMRS). Linear regression models were created to examine the effect of M/P (FACIT-Sp) upon QOL, symptoms, and other measures of mental well-being. These models adjusted for the effect of site, race, age, stage, anaphylaxis to chemotherapy, and partner status as potential confounders. RESULTS: This study enrolled 104 patients from three separate sites. After adjusting for potential confounders, it was found that higher M/P predicted better QOL (FACT-O) (p < 0.0001). Higher M/P also predicted decreased death anxiety, depression, and anxiety (p ≤ 0.005). Finally, higher M/P predicted increased hope and coping scores (p ≤ 0.0005). CONCLUSIONS: Level of M/P is associated with several important mental and physical health states. This information may allow providers to identify patients at increased risk for mental/physical distress and may facilitate early referral to targeted psychotherapy interventions focused on improving patient QOL and decreasing anxiety and depression.
Authors: Dana M Chase; Helen Q Huang; Lari Wenzel; David Cella; Richard McQuellon; Harry J Long; David H Moore; Bradley J Monk Journal: Gynecol Oncol Date: 2012-02-01 Impact factor: 5.482
Authors: Vivian E von Gruenigen; Helen Q Huang; Karen M Gil; Heidi E Frasure; Deborah K Armstrong; Lari B Wenzel Journal: Gynecol Oncol Date: 2011-11-23 Impact factor: 5.482
Authors: K Basen-Engquist; D Bodurka-Bevers; M A Fitzgerald; K Webster; D Cella; S Hu; D M Gershenson Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: Mounica Vallurupalli; Katharine Lauderdale; Michael J Balboni; Andrea C Phelps; Susan D Block; Andrea K Ng; Lisa A Kachnic; Tyler J Vanderweele; Tracy A Balboni Journal: J Support Oncol Date: 2011-11-16
Authors: Hanneke W M van Laarhoven; Johannes Schilderman; Gijs Bleijenberg; Rogier Donders; Kris C Vissers; Constans A H H V M Verhagen; Judith B Prins Journal: Cancer Nurs Date: 2011 Jul-Aug Impact factor: 2.592
Authors: W Breitbart; B Rosenfeld; H Pessin; M Kaim; J Funesti-Esch; M Galietta; C J Nelson; R Brescia Journal: JAMA Date: 2000-12-13 Impact factor: 56.272
Authors: Maarten J Fischer; Marion E Wiesenhaan; Aukje Does-den Heijer; Wim C Kleijn; Johan W R Nortier; Adrian A Kaptein Journal: Br J Health Psychol Date: 2012-09-24
Authors: M A Price; M L Bell; D W Sommeijer; M Friedlander; M R Stockler; A Defazio; P M Webb; P N Butow Journal: Gynecol Oncol Date: 2013-04-08 Impact factor: 5.482
Authors: Mei Bai; Jane Dixon; Anna-Leila Williams; Sangchoon Jeon; Mark Lazenby; Ruth McCorkle Journal: Qual Life Res Date: 2016-06-08 Impact factor: 4.147
Authors: Lauren Z Davis; George M Slavich; Premal H Thaker; Michael J Goodheart; David P Bender; Laila Dahmoush; Donna M Farley; Kristian E Markon; Frank J Penedo; David M Lubaroff; Steve W Cole; Anil K Sood; Susan K Lutgendorf Journal: Cancer Date: 2015-06-10 Impact factor: 6.860
Authors: Julie G Walker; Terri S Armstrong; Barbara J O'Brien; Mark R Gilbert; Rebecca L Casarez; Christopher Fagundes; Cobi J Heijnen; Clark R Andersen; Ying Yuan; Jimin Wu; Geri LoBiondo-Wood Journal: Compr Psychoneuroendocrinol Date: 2021-11-19